NCIt definition : A human monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic
T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint
inhibitory and antineoplastic activities. Upon intravenous administration, firastotug
targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated
downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated
immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory
receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in
the downregulation of the immune system.;
UNII : 8B1J60R28A;
CAS number : 2750031-14-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2750031-14-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;